Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.81 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.81 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213348 | 0.99 | MEN1 (0.88) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| Potassium SCHEMBL3490489 | 0.99 | MEN1 (0.86) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| SCHEMBL6056618 | 0.93 | MEN1 (0.75) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| SCHEMBL238048 | 0.93 | MEN1 (1.00) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| SCHEMBL29409702 | 0.93 | MEN1 (1.00) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| Potassium SCHEMBL6056620 | 0.92 | MEN1 (0.75) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| SCHEMBL3489772 | 0.90 | PTGER4 (1.00) | MEN1KMT2APTGER4PTGER3AGTR1 | |
| SCHEMBL9565990 | 0.89 | AGTR1 (0.84) | PTGER4PTGER3AGTR1 | |
| SCHEMBL9565999 | 0.89 | AGTR1 (0.83) | AGTR1 | |
| SCHEMBL9565941 | 0.88 | AGTR1 (0.86) | PTGER4PTGER3AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035868-A1 | METHODS OF TREATMENT OF UTERINE PATHOLOGICAL CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2010-02-11 | — | — | US | claimed |
| US-20080206309-A1 | ANTAGONISTS OF PROSTAGLANDIN RECEPTORS EP2 AND/OR EP4 FOR THE TREATMENT OF DYSMENORRHEA AND MENORRHAGIA | MEDICAL RESEARCH COUNCIL (GB) | 2008-08-28 | — | — | US | claimed |
| US-20080194666-A1 | Combination Treatment Methods | MEDICAL RESEARCH COUNCIL (GB) | 2008-08-14 | — | — | US | claimed |
| EP-1450813-B1 | ANTAGONISTS OF PROSTAGLANDIN RECEPTORS EP2 AND/OR EP4 FOR THE TREATMENT OF MENORRHAGIA | MEDICAL RES COUNCIL (GB) | 2007-08-29 | — | — | EP | claimed |
| US-20070004620-A1 | Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus | MEDICAL RESEARCH COUNCIL (GB) | 2007-01-04 | — | — | US | claimed |
| WO-2006106311-A2 | COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2006-10-12 | — | — | WO | claimed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | claimed |
| US-20060166872-A1 | Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia | EDINBURGH, THE UNIVERSITY COURT OF THE UNIVERSITY OF (GB) | 2006-07-27 | — | — | US | claimed |
| US-20050059742-A1 | Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia | MEDICAL RESEARCH COUNCIL (GB) | 2005-03-17 | — | — | US | claimed |
| EP-1511514-A1 | FP RECEPTOR ANTAGONISTS OR PGF2 ALPHA ANTAGONISTS FOR TREATING PATHOLOGICAL CONDITIONS OF THE UTERUS | Medical Research Council (GB) | 2005-03-09 | — | — | EP | claimed |
| WO-2003037348-A1 | ANTAGONISTS OF PROSTAGLANDIN RECEPTORS EP2 AND/OR EP4 FOR THE TREATMENT OF DYSMENORRHEA AND MENORRHAGIA | MEDICAL RESEARCH COUNCIL (GB) | 2003-05-08 | — | — | WO | claimed |
| WO-2003030911-A1 | USE OF PROSTAGLANDIN E SYNTHASE INHIBITORS, OR EP2 OR EP4 RECEPTOR ANTAGONISTS, IN THE TREATMENT OF A PATHOLOGICAL CONDITION OF THE UTERUS | MEDICAL RESEARCH COUNCIL (GB) | 2003-04-17 | — | — | WO | claimed |
| EP-1148877-A4 | METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2003-01-22 | — | — | EP | claimed |
| JP-2002527393-A | — | — | 2002-08-27 | — | — | JP | claimed |
| US-6414006-B1 | ADMINISTERING A PROSTAGLANDIN RECEPTOR EP4 SUBTYPE ANTAGONIST; TREATING BONE DISORDERS SUCH AS OSTEOPOROSIS AND PAGET'S DISEASE; WORKS BY INHIBITING THE BONE RESORPTION OF THE OSTEOCLASTS | MERCK FROSST CANADA & CO. (CA) | 2002-07-02 | — | — | US | claimed |
| US-20020082287-A1 | METHODS FOR INHIBITING BONE RESORPTION | MERCK FROSST CANADA LTD. (CA) | 2002-06-27 | — | — | US | claimed |
| EP-1148877-A1 | METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| US-20010018433-A1 | Administering a bisphosphonate compound; prostaglandin antagonist | MERCK & CO., INC. | 2001-08-30 | — | — | US | claimed |
| US-20010012838-A1 | Methods for inhibiting bone resorption | MERCK & CO., INC. | 2001-08-09 | — | — | US | claimed |
| WO-2000021532-A1 | METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 2000-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194666-A1 | Combination Treatment Methods | GNRHR, SHBG, FSHR | MEN1 1334/4885KMT2A 2899/4885PTGER4 25/4885 |
| US-20020082287-A1 | METHODS FOR INHIBITING BONE RESORPTION | PTGER4, PTGER1, PTGER3 | MEN1 3372/4885KMT2A 2422/4885PTGER4 1/4885 |
| US-20010018433-A1 | Administering a bisphosphonate compound; prostaglandin antagonist | PTGER4, PTGER1, PTGER2 | MEN1 2541/4885KMT2A 3695/4885PTGER4 1/4885 |
| US-20010012838-A1 | Methods for inhibiting bone resorption | PTGER4, PTGER1, PTGER3 | MEN1 3372/4885KMT2A 2422/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.